JP2024516843A - 抗ｔｉｇｉｔ抗体、抗ｃｄ９６抗体、及びそれらの使用の方法 - Google Patents

抗ｔｉｇｉｔ抗体、抗ｃｄ９６抗体、及びそれらの使用の方法 Download PDF

Info

Publication number
JP2024516843A
JP2024516843A JP2023568081A JP2023568081A JP2024516843A JP 2024516843 A JP2024516843 A JP 2024516843A JP 2023568081 A JP2023568081 A JP 2023568081A JP 2023568081 A JP2023568081 A JP 2023568081A JP 2024516843 A JP2024516843 A JP 2024516843A
Authority
JP
Japan
Prior art keywords
antigen
amino acid
binding region
seq
multispecific molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516843A5 (https=
JPWO2022236276A5 (https=
Inventor
ダン・シッダールタ・チャンド
ザーラ・ジャワド
オルガ・イグナトヴィッチ
ニコラ・アン・ラムゼイ
スペンサー・キャンベル
ベス・ウェンズリー
エマニュエル・シリル・パスカル・ブライエンド
ケー・マーク・ブシェル
ベンジャミン・マキシム・モーリン
ヴェロニカ・フランチスカ・イルコウ
Original Assignee
アジェナス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェナス インコーポレイテッド filed Critical アジェナス インコーポレイテッド
Publication of JP2024516843A publication Critical patent/JP2024516843A/ja
Publication of JP2024516843A5 publication Critical patent/JP2024516843A5/ja
Publication of JPWO2022236276A5 publication Critical patent/JPWO2022236276A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023568081A 2021-05-04 2022-05-04 抗ｔｉｇｉｔ抗体、抗ｃｄ９６抗体、及びそれらの使用の方法 Pending JP2024516843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201537P 2021-05-04 2021-05-04
US63/201,537 2021-05-04
PCT/US2022/072099 WO2022236276A2 (en) 2021-05-04 2022-05-04 Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024516843A true JP2024516843A (ja) 2024-04-17
JP2024516843A5 JP2024516843A5 (https=) 2025-05-14
JPWO2022236276A5 JPWO2022236276A5 (https=) 2025-05-14

Family

ID=83933041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568081A Pending JP2024516843A (ja) 2021-05-04 2022-05-04 抗ｔｉｇｉｔ抗体、抗ｃｄ９６抗体、及びそれらの使用の方法

Country Status (16)

Country Link
US (2) US11718669B2 (https=)
EP (1) EP4333893A4 (https=)
JP (1) JP2024516843A (https=)
KR (1) KR20240006054A (https=)
CN (1) CN117425494A (https=)
AR (1) AR125753A1 (https=)
AU (1) AU2022271331A1 (https=)
BR (1) BR112023022319A2 (https=)
CA (1) CA3217289A1 (https=)
CL (1) CL2023003244A1 (https=)
CO (1) CO2023016037A2 (https=)
IL (1) IL308157A (https=)
MX (1) MX2023013078A (https=)
PE (1) PE20240369A1 (https=)
TW (1) TW202304965A (https=)
WO (1) WO2022236276A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
WO2025188697A1 (en) * 2024-03-04 2025-09-12 Agenus Inc. Methods of treating cancer using anti-cd96/anti-tigit antibodies and combination therapies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204363A1 (en) * 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
WO2020132034A1 (en) * 2018-12-20 2020-06-25 23Andme, Inc. Anti-cd96 antibodies and methods of use thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
EP3214095B1 (en) 2005-05-12 2019-12-11 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
WO2007141274A2 (en) 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2013160396A1 (en) 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
MX2014014951A (es) 2012-06-06 2015-03-13 Oncomed Pharm Inc Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
CN105102480B (zh) 2012-12-24 2019-04-16 艾伯维公司 催乳素受体结合蛋白及其用途
CA2916681A1 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
PL3036258T3 (pl) 2013-08-22 2023-12-11 The Council Of The Queensland Institute Of Medical Research Modulowanie receptora dla leczenia raka i infekcji wirusowych
WO2015035112A1 (en) 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
CA2922950A1 (en) * 2013-09-30 2015-04-02 Shinya Ishii Method for producing antigen-binding molecule using modified helper phage
AU2015228372B2 (en) 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
WO2015143343A2 (en) 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
EP3144388B1 (en) 2014-05-13 2020-07-01 Chugai Seiyaku Kabushiki Kaisha T cell-redirecting antigen-binding molecule for cells having immunosuppression function
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
SG11201700258VA (en) 2014-07-16 2017-02-27 Genentech Inc Methods of treating cancer using tigit inhibitors and anti-cancer agents
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
BR112017008399A2 (pt) 2014-10-24 2018-06-19 StemImmune, Incorporated abordagem de imunoterapia de combinação para tratamento de câncer
KR20170072343A (ko) 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
CN107207594B (zh) 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
WO2016154544A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2016180781A1 (en) 2015-05-08 2016-11-17 Michele Maio Combination therapy of mesothelioma
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
EP3328363A4 (en) 2015-07-31 2019-08-21 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHOD FOR IMMUNOMODULATION
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3334757A4 (en) 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
EP3349792A1 (en) 2015-09-14 2018-07-25 Compass Therapeutics LLC Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
CA2994858C (en) * 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
PL3356413T3 (pl) 2015-10-01 2022-04-19 Potenza Therapeutics, Inc. Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
CN114181960B (zh) 2015-10-09 2024-08-23 美天施生物科技有限公司 嵌合抗原受体和使用方法
EP3402517B1 (en) 2016-01-15 2025-08-20 RFEMB Holdings, LLC Immunologic treatment of cancer by using a tumor ablation technic together with a combination of a ctla-4 inhibitor, a pd-1 inhibitor and gm-csf
WO2017152088A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
WO2017218970A1 (en) 2016-06-17 2017-12-21 Varian Medical Systems, Inc. Immune modulators in combination with radiation treatment
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
CN110088132B (zh) 2016-08-17 2020-10-27 康姆普根有限公司 抗tigit抗体，抗pvrig抗体及其组合
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
EP3589313A4 (en) 2017-02-28 2021-05-19 Seagen Inc. ANTI-TIGITE ANTIBODY
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
JP7402693B2 (ja) 2017-05-02 2023-12-21 メルク・シャープ・アンド・ドーム・エルエルシー 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
IL272227B2 (en) 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
CN111655286A (zh) 2017-08-11 2020-09-11 布林克生物医学简易股份公司 作为免疫调节剂的cd96结合剂
US11512129B2 (en) 2017-09-29 2022-11-29 Jiangsu Hengrui Medicine Co., Ltd. TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
WO2019091449A1 (zh) 2017-11-10 2019-05-16 江苏恒瑞医药股份有限公司 Cd96抗体、其抗原结合片段及医药用途
TW201930358A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
TWI816729B (zh) * 2017-12-30 2023-10-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
KR20200109313A (ko) 2018-01-15 2020-09-22 난징 레전드 바이오테크 씨오., 엘티디. Tigit에 대한 항체 및 이의 변이체
WO2019152574A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
CA3086936C (en) 2018-02-06 2022-11-29 I-Mab Biopharma Us Limited Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
CN111836831A (zh) 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
MX2020008795A (es) 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
EA202191176A1 (ru) * 2018-10-31 2021-07-28 Делиниа, Инк. Поливалентные модуляторы регуляторных т-клеток
EP3938396A1 (en) * 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
TWI760751B (zh) 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
CA3285695A1 (en) * 2019-06-26 2026-03-02 Ap Biosciences, Inc. Antibodies for t-cell activation
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
CN117241827A (zh) * 2021-05-04 2023-12-15 艾吉纳斯公司 抗tigit抗体及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204363A1 (en) * 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
WO2020132034A1 (en) * 2018-12-20 2020-06-25 23Andme, Inc. Anti-cd96 antibodies and methods of use thereof

Also Published As

Publication number Publication date
AU2022271331A1 (en) 2023-10-26
EP4333893A2 (en) 2024-03-13
BR112023022319A2 (pt) 2024-02-20
CA3217289A1 (en) 2022-11-10
CO2023016037A2 (es) 2023-11-30
AR125753A1 (es) 2023-08-09
MX2023013078A (es) 2023-11-16
US12479913B2 (en) 2025-11-25
WO2022236276A2 (en) 2022-11-10
US20230014036A1 (en) 2023-01-19
TW202304965A (zh) 2023-02-01
US20240141039A1 (en) 2024-05-02
CN117425494A (zh) 2024-01-19
EP4333893A4 (en) 2025-06-18
AU2022271331A9 (en) 2023-11-09
WO2022236276A3 (en) 2023-01-19
IL308157A (en) 2024-01-01
PE20240369A1 (es) 2024-03-04
CL2023003244A1 (es) 2024-04-19
US11718669B2 (en) 2023-08-08
KR20240006054A (ko) 2024-01-12

Similar Documents

Publication Publication Date Title
JP7395554B2 (ja) 抗ｃｔｌａ－４抗体およびそれらの使用方法
JP7369233B2 (ja) 抗ｌａｇ－３抗体及びその使用方法
KR102629972B1 (ko) 항-cd137 항체 및 이의 사용 방법
JP2023083455A (ja) 抗ｔｉｍ－３抗体及びその使用方法
US11680098B2 (en) Antibodies that specifically bind human CD96
US12479913B2 (en) Polynucleotide encoding anti-TIGIT and anti-CD96 antibodies
US20220389095A1 (en) Anti-tigit antibodies and methods of use thereof
US20250109201A1 (en) Anti-ilt2 antibodies and uses thereof
HK40076263A (en) Anti-cd96 antibodies and methods of use thereof
EA043100B1 (ru) Антитела против tim-3 и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310